Percentages of bisbenzimide-labeled cells colocalizing with specific markers GFAP, MAP-2 and Neu-N were significantly higher in the U-IGF1R+ hDSC-treated rats (≈9.5%, ≈12%, and ≈10%) than that in the F-IGF1R+ hDSC-treated rats (≈4%, ≈5%, and ≈4%), suggesting a higher neurogenesis rate in stroke rats receiving U-IGF1R+ hDSCs treatment. Here, RBFOX3 is linked to stroke disorder.